MicroRNAs as biomarkers for clinical studies

The development of better diagnostic and prognostic non-invasive biomarkers holds an enormous potential to improve the ability to diagnose and individualize treatment of a great number of human diseases and substantially reduce health care cost. The discovery of a fundamental role of microRNAs in the disease pathogenesis and their presence and stability in biological fluids has led to extensive investigation of the role of microRNAs as potential non-invasive biomarkers for disease diagnosis and prognosis. The result of this research has suggested that alterations of microRNAs may be sensitive indicators of various pathologies; however, despite the indisputable progress in this field, the diagnostic promise of microRNAs has remained a work in progress, and circulating microRNAs have not entered the field of clinical medicine yet. Commonly reported microRNAs as disease biomarkers are largely not disease-specific and the results are often contradicting in independent studies. This review summarizes the current knowledge on the role of microRNAs as disease indicators and emphasizes the current gaps, challenges, and questions that need to be addressed in future well-designed and well-controlled studies for a successful translation of microRNA profiling into clinically meaningful tests. Impact statement This review summarizes the current knowledge on the role of circulating miRNAs as clinical diagnostic biomarkers and highlights the challenges that need to be addressed in future studies for a successful translation of circulating miRNAs into a novel diagnostic tool.

[1]  J. Kleinjans,et al.  Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human , 2017, PloS one.

[2]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[3]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[4]  A. Warth,et al.  Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. , 2013, Lung cancer.

[5]  P. Reddy,et al.  Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? , 2016, Biochimica et biophysica acta.

[6]  F. Zhan,et al.  Low serum miR‐19a expression as a novel poor prognostic indicator in multiple myeloma , 2015, International journal of cancer.

[7]  Hongwei Wang,et al.  Expression of Serum Exosomal MicroRNA-21 in Human Hepatocellular Carcinoma , 2014, BioMed research international.

[8]  I. Pogribny,et al.  The role for microRNAs in drug toxicity and in safety assessment , 2015, Expert opinion on drug metabolism & toxicology.

[9]  D. Schadendorf,et al.  The validity of circulating microRNAs in oncology: Five years of challenges and contradictions , 2014, Molecular oncology.

[10]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[11]  K. Zen,et al.  A Five-miRNA Panel Identified From a Multicentric Case–control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients , 2015, EBioMedicine.

[12]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[13]  E. Cavarretta,et al.  MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena? , 2016, BioMed research international.

[14]  Xiao-jing Yang,et al.  A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. , 2015, The Lancet. Oncology.

[15]  Michael J Kerin,et al.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.

[16]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[17]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[18]  S. Rome,et al.  Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. , 2015, Journal of molecular biomarkers & diagnosis.

[19]  R. Schnabel,et al.  Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study , 2016, European heart journal.

[20]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Ping Shi,et al.  Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction , 2016, Molecular medicine reports.

[22]  Kenneth W Witwer,et al.  Circulating microRNA biomarker studies: pitfalls and potential solutions. , 2015, Clinical chemistry.

[23]  C. Hammer,et al.  Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis , 2015, PloS one.

[24]  Chien‐Hung Yeh,et al.  Clinical significance of microRNAs in chronic and acute human leukemia , 2016, Molecular Cancer.

[25]  Y. Toiyama,et al.  Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer , 2014, Annals of surgery.

[26]  De-chun Zhang,et al.  Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis , 2016, Clinical and Experimental Medicine.

[27]  A. Schetter,et al.  Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. , 2015, Journal of the National Cancer Institute.

[28]  William M. Lee Drug-induced acute liver failure. , 2013, Clinics in liver disease.

[29]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[30]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[31]  H. Brenner,et al.  Plasma miR‐122 and miR‐200 family are prognostic markers in colorectal cancer , 2017, International journal of cancer.

[32]  W. Jin,et al.  Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis , 2014, Molecules.

[33]  Massimo Negrini,et al.  Absolute quantification of cell-free microRNAs in cancer patients , 2015, Oncotarget.

[34]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[35]  Ziyuan Zhao,et al.  Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer , 2014, Tumor Biology.

[36]  Ke Li,et al.  Serum MicroRNA-21 as a Diagnostic Marker for Lung Carcinoma: A Systematic Review and Meta-Analysis , 2014, PloS one.

[37]  P. Watkins,et al.  The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers , 2012, Clinical pharmacology and therapeutics.

[38]  P. Watkins,et al.  Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine , 2014, BMC Pharmacology and Toxicology.

[39]  Andreas Trumpp,et al.  Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. , 2016, Carcinogenesis.

[40]  M. Mayr,et al.  MicroRNAs in Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.

[41]  Y. Toiyama,et al.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.

[42]  A. Sanyal,et al.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis , 2014, Gut.

[43]  Q. Lu,et al.  The emerging role of circulating microRNAs as biomarkers in autoimmune diseases , 2014, Autoimmunity.

[44]  X. Chen,et al.  A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[45]  Jonathan Moggs,et al.  Circulating microRNAs as potential markers of human drug‐induced liver injury , 2011, Hepatology.

[46]  Alasdair J Gray,et al.  Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital , 2013, Hepatology.

[47]  Xianyin Lai,et al.  A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer , 2017, Cancer letters.

[48]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[49]  S. Szeinbach,et al.  Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 , 2011, Pharmacoepidemiology and drug safety.

[50]  Y. Devaux,et al.  Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain , 2015, Journal of internal medicine.

[51]  Q. Pan,et al.  Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population , 2016, World journal of gastroenterology.

[52]  Paola Tiberio,et al.  Challenges in Using Circulating miRNAs as Cancer Biomarkers , 2015, BioMed research international.

[53]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[54]  Y. Devaux,et al.  A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction , 2013, PloS one.

[55]  P. Dargan,et al.  Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury , 2015, Scientific Reports.

[56]  D. Kriebel,et al.  The increasing toll of adolescent cancer incidence in the US , 2017, PloS one.

[57]  F. Mancarella,et al.  Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging? , 2017, Journal of Endocrinological Investigation.

[58]  William Pao,et al.  AACR Cancer Progress Report 2016 , 2016, Clinical Cancer Research.

[59]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[60]  G. Goodall,et al.  Circulating microRNAs predict biochemical recurrence in prostate cancer patients , 2013, British Journal of Cancer.

[61]  Z. Massy,et al.  Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study , 2016, Clinical kidney journal.

[62]  X. Yao,et al.  Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy , 2011, The Prostate.

[63]  J. Bauersachs,et al.  Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.

[64]  L. Räber,et al.  Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction , 2016, European heart journal.

[65]  Yuling Hong,et al.  Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020 , 2016, Preventing chronic disease.

[66]  Wang He,et al.  Diagnostic value of circulating miR-21: An update meta-analysis in various cancers and validation in endometrial cancer , 2016, Oncotarget.

[67]  S. Gordon,et al.  Circulating microRNAs as Potential Biomarkers of Infectious Disease , 2017, Front. Immunol..

[68]  Jiri Aubrecht,et al.  Development of Blood Biomarkers for Drug-Induced Liver Injury: An Evaluation of Their Potential for Risk Assessment and Diagnostics , 2013, Molecular Diagnosis & Therapy.

[69]  H. Jäck,et al.  Serum microRNAs as powerful cancer biomarkers. , 2010, Biochimica et biophysica acta.

[70]  M. Denti,et al.  Circulating miRNAs as Biomarkers for Neurodegenerative Disorders , 2014, Molecules.

[71]  Yongzhi Yang,et al.  Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer , 2017, Oncotarget.

[72]  P. Doevendans,et al.  Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome , 2013, Journal of Cardiovascular Translational Research.

[73]  Jenna Khan,et al.  Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs , 2017, Clinical chemistry and laboratory medicine.

[74]  H. Baba,et al.  Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma , 2013, Cancer.

[75]  D. Fliser,et al.  Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[76]  A. Mebazaa,et al.  Circulating microRNAs and Outcome in Patients with Acute Heart Failure , 2015, PloS one.

[77]  A. Laucevičius,et al.  Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review , 2016, Cardiovascular research.

[78]  Victor R. Ambros,et al.  Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis , 2014, Proceedings of the National Academy of Sciences.